Evaluating the Effectiveness of Yttrium-90 Glass Microspheres in the Treatment of Hepatocellular Carcinoma, Intrahepatic Cholangiocarcinoma, and Metastatic Colorectal Cancer in Practice: Protocol for the Prospective PROACTIF Phase IV Registry Study in Fra
Fiche publication
Date publication
novembre 2021
Journal
Cardiovascular and interventional radiology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MANFREDI Sylvain
Tous les auteurs :
Garin E, Pinaquy JB, Bailly C, Sengel C, Mariano-Goulart D, Edeline J, Blanc JF, Bouvier A, Tordo J, Rode A, Becker S, Sefrioui D, de Baere T, Somma C, Mastier C, Goupil J, Chevallier P, Regnault H, Vibert E, Manfredi S, Vicaut E, Patel B, Boucher E, Guiu B,
Lien Pubmed
Résumé
Recently, selective internal radiation therapy using yttrium-90 (Y90) glass microspheres (TheraSphere™) was approved for reimbursement by health authorities in France. The PROACTIF study aims to gather data on effectiveness, patient quality of life, and safety with use of Y90 glass microspheres in real-world clinical settings in France.
Mots clés
Hepatocellular carcinoma, Intrahepatic cholangiocarcinoma, Liver metastatic colorectal cancer, Selective internal radiation therapy, Yttrium-90
Référence
Cardiovasc Intervent Radiol. 2021 Nov 18;: